3621 W MacArthur Blvd Suite 107 Santa Ana, CA 92704
Toll Free – (844)-500-1351 Local – (714)-604-1416 Fax – (714)-907-1115

Gross-tasting medications can be a barrier to treatment. Philly researchers developed a ‘bitter blocker’ to help.

Rent Computer Hardware You Need, When You Need It

Aubrey Whelan | (TNS) The Philadelphia Inquirer

Peihua Jiang knows how difficult it can be to convince a child to take a sip of a bitter liquid medication.

When they were young, his kids sometimes balked at taking medicines because they didn’t like how they tasted. And as a neurobiologist, Jiang knew the medical issues at stake went beyond a minor inconvenience.

Swallowing pills can be difficult for many young children and elderly people. Liquid medications are easier to consume, but their taste is often so off-putting that some patients will avoid them entirely — a significant barrier to good health for those who need to take lifesaving medications.

“My kids would refuse to take medicine when they were young,” he said, laughing. “It’s evolution; it makes perfect sense. A bitter taste is a sign you’re not supposed to eat something. But with medicine, it’s a different story.”

That’s why Jiang and his colleagues at Philadelphia’s Monell Chemical Senses Center, have spent years taking on what they describe as one of the most enduring challenges in medicine ― finding a “bitter blocker” substance that can prevent a patient from tasting anything bitter.

This month, Jiang and several colleagues announced a breakthrough: They identified a nerve inhibitor in liquid form that temporarily blocks all taste entirely. The center says it’s the first temporary taste blocker that works universally in humans, and a game-changer in a yearslong research journey.

“We are very pumped,” said Carol Christensen, a consultant to the director at Monell and a coauthor with Jiang of a paper on the compound recently published in British Journal of Pharmacology.

How bitter medication hurts health outcomes

Researchers at Monell, an independent research institution devoted to studying the senses of taste and smell, first began developing a bitter blocker in 2016 with a grant from the Bill and Melinda Gates Foundation. The foundation was concerned about bitter tastes preventing the uptake of medications in developing countries, where many people need to take regular medication for serious chronic illnesses like HIV and tuberculosis.

Ninety percent of U.S. pediatricians cited “a drug’s taste and palatability” as the biggest barrier to getting their patients to complete a course of medication, according to a 2013 review of existing research on bitter medications for children.

The paper noted it’s also hard for young children to swallow pills, even in small sizes, and that people of all ages, especially elderly adults, can have issues taking pills.

And what one might call the Mary Poppins method — a spoonful of sugar to make the medicine go down — comes with its own risks. Adding sweeteners to medications can cause cavities or damage tooth enamel.

For patients with serious conditions that require a long course of treatment, such as HIV, avoiding bitter medications can be dangerous.

“Many, many children, especially in developing countries, are not taking medicines and are dying,” said Linda Flammer, a senior research associate at Monell and the lead author on the new paper. “Simply giving them medication they can tolerate will save their lives.”

‘It’s actually really wonderful’

At first, Monell researchers hoped to develop a bitter blocker by targeting the taste receptors on the tongue that handle bitter sensations. But that’s more complicated than it seems.

Sweet tastes are easier to block, because they affect only two taste receptors on the tongue. But at least 25 taste receptors are devoted to detecting bitter tastes. And a person’s reaction to a bitter taste can vary depending on their genetics.

“Some may have a strong response to one bitter receptor. Some people may not have any response at all,” Flammer said.

So the researchers pivoted to target the nerve receptor that receives signals from the taste buds, Jiang said. In their search, they identified clinical trials for medications that targeted the same nerve receptor to treat various health conditions.

In trials for one of those medications, designed to treat chronic cough, the researchers noticed a curious side effect. “People were taking these medications for chronic cough, but they were saying, ‘It messed up my taste,’” Jiang said. They theorized they might be able to adapt a nerve inhibitor used in the medication to intentionally target a person’s sense of taste.

They discovered that the compound in liquid form, swished around the mouth for less than a minute, blocks all taste for about an hour and a half. Then, taste returns to normal, allowing a patient to go about their daily lives without a bitter taste lingering in their mouths.

The researchers tested it on adult humans and on mice, and found that the inhibitor only blocks taste — not any other sensations in the mouth, like temperature or even the tingling felt from a sip of a carbonated beverage.

“It’s actually really wonderful. We’ve never seen that before,” Jiang said.

Getting the treatment to patients

The bitter blocker is a long way from seeing practical applications in medicine, the researchers said. In general, between further research and safety testing, it can take years for a scientific discovery to roll out to the general public. But drug manufacturers could one day deliver the drug through lollipops, popsicles, or other kid-friendly forms to help young children feel more confident about taking their medications, Jiang said.

“We just hope now that we can take this very exciting finding and then find the right partners and the next funding to really make it happen,” said his colleague, Christensen.

Jiang is also hoping to continue studies on other bitter blockers, including ones that specifically target taste buds.

“We tried to provide a toolbox for blocking bitterness,” he said.

___

©2024 The Philadelphia Inquirer, LLC. Visit at inquirer.com. Distributed by Tribune Content Agency, LLC.

Generated by Feedzy